TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05504772

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
Study: NCT05124626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIRPE with one bar
Description: Minimally invasive repair of pectus excavatum utilizing one metallic bar
Study: NCT05504772

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
Study: NCT05555550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine
Description: 18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
Study: NCT04847544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629 administered orally twice daily (BID) for up to 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally BID for up to 28 days.
Study: NCT05504772

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

Intervention type: GENETIC
Intervention: DNA Methylation
Description: Genome-wide assessment of DNA methylation will be conducted on all samples where possible.

Intervention type: GENETIC
Intervention: DNA Methylation
Description: Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
Study: NCT06095830

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
Study: NCT06329050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Administration of Losartan tablets(50 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo tablets
Study: NCT05200793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 10 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
Study: NCT04325503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa
Description: carbidopa and carbidopa-levodopa standard treatment
Study: NCT06062719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI group
Description: 80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI plus octreotide
Description: octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
Study: NCT03467906

Intervention type: OTHER
Intervention: In-laboratory assessment
Description: Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.

Intervention type: OTHER
Intervention: In-laboratory assessment
Description: Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
Study: NCT04766866

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation
Description: A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
Study: NCT05991024

Intervention type: BEHAVIORAL
Intervention: the incisional hernia recurrent
Description: Recurrence after repair was the main outcome
Study: NCT05134220

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Calcium
Description: * Serum calcium level.~* Serum phosphorus level. will be measured to all study population

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Calcium
Description: * Serum calcium level.~* Serum phosphorus level. will be measured to all study population
Study: NCT05565053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral thoracal erector spinae plane block
Description: Bilateral upper thoracal erector spinae plane block with ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapezius muscle trigger point injection
Description: Trapezius muscle trigger point injection
Study: NCT05079425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC736
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC736
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC736
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study: NCT05504772

Intervention type: GENETIC
Intervention: DNA Methylation
Description: Genome-wide assessment of DNA methylation will be conducted on all samples where possible.

Intervention type: GENETIC
Intervention: DNA Methylation
Description: Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
Study: NCT05033743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole 2 GM Oral Granules
Description: Once weekly 2g oral secnidazole for 18 weeks
Study: NCT05079425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study: NCT06223893

Intervention type: DEVICE
Group type: OTHER
Intervention: CirrhoCare management system
Description: This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring.
Study: NCT04826874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect labeling
Description: Short behavioral intervention teaching affect labeling
Study: NCT05194319

Intervention type: OTHER
Intervention: All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)
Description: The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .

Intervention type: OTHER
Intervention: All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)
Description: The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
Study: NCT05504772

Intervention type: GENETIC
Intervention: Targeted Panel Sequencing
Description: Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type

Intervention type: GENETIC
Intervention: Targeted Panel Sequencing
Description: Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type
Study: NCT06518291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG
Description: Comparing two drugs in UTI treatment
Study: NCT04761861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: Vildagliptin 50 MG tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet daily
Study: NCT04965454

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorine-18 fluorocholine
Description: 18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
Study: NCT04808648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: tablet, oral, 200 mg once daily for day 1 and day 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: tablet, oral, 200 mg once daily for day 1 and day 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: capsule, oral, 200 mg twice daily for day 8 to day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: capsule, oral, 600 mg once daily for day 8 to day 16
Study: NCT05006053

Intervention type: OTHER
Intervention: Interviews/Focus groups
Description: Qualitative study (no intervention delivered)
Study: NCT05207761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565
Description: Q.D. in both eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565
Description: Q.D. in both eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930
Description: T.I.D in both eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930
Description: T.I.D in both eye
Study: NCT06518291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: treatment of UTI
Study: NCT06484166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fullerene cream
Description: Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trolamine (Biafine)
Description: Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
Study: NCT05167201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
Study: NCT05142735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 2000 mg (4 x 500-mg tablets) every morning

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets every morning
Study: NCT05331261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacanent surgery
Description: Breath exercises
Study: NCT04660747

Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
Study: NCT06559254

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
Study: NCT05115357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecto-Intercostal Fascial Block
Description: A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Thoracis Muscle Plane Block
Description: The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
Study: NCT04079088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.
Study: NCT05504772

Intervention type: OTHER
Intervention: Liquid Biopsy
Description: Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.

Intervention type: OTHER
Intervention: Liquid Biopsy
Description: Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
Study: NCT04079088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.
Study: NCT04766853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronic Acid 20mg/2ml
Study: NCT05087030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-14-P
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-14-P
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-14-P
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.